Breast Cancer: EA1131

EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy


The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer.

Patients that are eligible for this study include:

  1. Patients that have breast cancer that does not have the estrogen, progesterone or HER2 receptor, which is called triple-negative breast cancer
  2. Patients that have completed all chemotherapy prior to surgery
  3. Patients that had greater than or equal to 1 cm worth of cancer in the breast at the time of surgery
  4. Patient that have completed radiation treatment after surgery, if indicated

For more information please visit the National Cancer Institute.


1. Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number: 563-421-1900

2. Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3. Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number: 563-345-4325

Clinical Trial Categories

  • Breast Cancer
Eastern Cooperative Oncology Group
Kim Turner, R.N. at 563-421-1908


  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office